BioSpace News Archive

OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced that the first patient was treated in the Company’s First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority

Demand for Medical and Dental IP&C solutions continue to outpace elective procedure volume Strong recurring revenue mix and continued cost discipline driving higher profitability - Net sales of $294.0M, up 1.9% - GAAP diluted EPS of $0.27, up $0.32 versus prior year - Non-GAAP diluted EPS of $0.79, up 29.5% - GAAP net income of $12.1M, up $14.3M versus prior year

Allurion Technologies , a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced promotions in its Commercial Team including Benoit Chardon to Chief Commercial Officer, Camillo Docimo to Vice President of Program Excellence, and Javier Ibanez to Vice President of International Sales.

Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors Maverick’s lead candidate TAK-186 (formerly MVC-101), a conditionally active T-cell engager, is first in its class to enter the clinic with recent Phase 1/2 study initiation

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, reported financial results for the fourth quarter and full year ended December 31, 2020.

Gvoke® net sales of $20.2 million for full-year 2020 Continued Gvoke prescription growth – over 350% in 2020 Strong cash position of $133.8 million Conference call and webcast today at 8:30 a.m. ET

– Primary and secondary endpoints were met, key exploratory endpoints supported clinical benefit in Phase 3 study of omidubicel in patients with hematologic malignancies; BLA submission anticipated in fourth quarter of 2021- — Omidubicel commercial preparation underway, including the creation of Gamida Cell Assist, to support potential launch —

Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS) Provides update on COVID-19 testing with more than 300,000 samples received

PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17)